Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

Company profile

Robert Bradway
Fiscal year end
Former names
IRS number

AMGN stock data



8 Feb 21
18 Apr 21
31 Dec 21
Quarter (USD)
Dec 20 Sep 20 Jun 20 Mar 20
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from AMGEN earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 6.27B 6.27B 6.27B 6.27B 6.27B 6.27B
Cash burn (monthly) 940.33M (positive/no burn) (positive/no burn) (positive/no burn) (positive/no burn) (positive/no burn)
Cash used (since last report) 3.39B n/a n/a n/a n/a n/a
Cash remaining 2.88B n/a n/a n/a n/a n/a
Runway (months of cash) 3.1 n/a n/a n/a n/a n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
14 Apr 21 Ronald D Sugar Common Stock Sell Dispose S No Yes 249.98 1,000 249.98K 15,927
14 Apr 21 Ronald D Sugar Common Stock Option exercise Aquire M No No 71.64 1,000 71.64K 16,927
14 Apr 21 Ronald D Sugar Nqso Common Stock Option exercise Dispose M No No 71.64 1,000 71.64K 1,000
19 Mar 21 Robert A Bradway Common Stock Payment of exercise Dispose F No No 244.42 21,190 5.18M 589,262
19 Mar 21 Gordon Murdo Common Stock Payment of exercise Dispose F No No 244.42 8,989 2.2M 41,458
19 Mar 21 Jonathan P Graham Common Stock Payment of exercise Dispose F No No 244.42 4,360 1.07M 44,529
19 Mar 21 Nancy A. Grygiel Common Stock Payment of exercise Dispose F No No 244.42 435 106.32K 12,051

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

76.0% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 2139 2078 +2.9%
Opened positions 236 143 +65.0%
Closed positions 175 105 +66.7%
Increased positions 876 829 +5.7%
Reduced positions 748 772 -3.1%
13F shares
Current Prev Q Change
Total value 101.49B 112.25B -9.6%
Total shares 437.38M 438.9M -0.3%
Total puts 4.08M 3.66M +11.7%
Total calls 3.65M 4.12M -11.4%
Total put/call ratio 1.1 0.9 +26.1%
Largest owners
Shares Value Change
BLK Blackrock 47.81M $10.99B -0.4%
Vanguard 47.23M $10.86B -1.5%
Capital Research Global Investors 31.76M $7.3B -5.2%
STT State Street 30.09M $6.92B -3.8%
Primecap Management 16.98M $3.9B -2.5%
FMR 13.78M $3.17B -3.0%
MS Morgan Stanley 9.75M $2.24B +13.8%
Geode Capital Management 8.8M $2.02B -4.0%
NTRS Northern Trust 7.92M $1.82B -2.7%
WFC Wells Fargo & Co. 7.61M $1.75B +2.6%
Largest transactions
Shares Bought/sold Change
Norges Bank 5.67M +5.67M NEW
JPM JPMorgan Chase & Co. 5.24M -3.03M -36.7%
Capital Research Global Investors 31.76M -1.74M -5.2%
STT State Street 30.09M -1.19M -3.8%
MS Morgan Stanley 9.75M +1.18M +13.8%
IVZ Invesco 2.17M -1.01M -31.8%
Boston Partners 972.58K +952.08K +4644.8%
UBS UBS Group AG - Registered Shares 3.24M +897.63K +38.3%
Capital International Investors 2.34M -759.45K -24.5%
Vanguard 47.23M -709.83K -1.5%
Content analysis
H.S. sophomore Avg
New words: AABP, AAER, accident, AECP, aflibercept, AISN, ALEN, Allergy, Alliance, ambition, AMD, AMP, amplify, amy, andChief, antibribery, anticorruption, antikickback, antiresorptive, arrive, Arthrex, autumn, AVEN, avoid, avoided, AVSOLA, backdoor, background, backlog, BARDA, BEIJERINCK, Biden, Biomedical, black, Blaylock, blended, BNP, body, BofA, bond, boosting, border, broadened, BSA, Businesswomen, calcimimetic, Career, Chinese, Cir, clarification, clear, coalition, CodeBreaK, cohort, college, combat, compulsory, concurrently, Connecticut, constitutionality, coordinated, copay, COVID, Crohn, culture, curfew, cutoff, cybersecurity, daily, deal, deceleration, dedesignate, deeper, Deficiency, defray, degeneration, dental, deplete, Deutsche, diagnosed, diminish, disciplined, dissemination, distancing, docetaxel, downturn, ease, ebb, ecosystem, edema, elderly, emphasize, Empowered, encompassing, endothelial, enduring, England, exacerbated, exacerbation, exempted, EYLEA, Fc, featured, Fed, fell, fleet, fluidity, foreseeable, foster, futility, globe, goal, Grygiel, Hampshire, healthy, HGRAC, HIV, hospital, hospitalized, ICOSL, ICS, IIIB, immune, immunodeficiency, immunosuppressive, impossible, incentivize, incident, Indian, inhaled, injury, inserted, instructing, intelligence, interfering, interlocutory, intermittent, internet, investee, joinder, Journal, KANJINTI, learning, left, legitimate, LGBTQ, linda, lockdown, logistical, louie, lp, macular, magnitude, makeup, manipulated, Maryland, MBA, medium, MFN, microscopic, mind, Minnesota, mission, mobile, motivate, motivating, multicenter, myriad, Nancy, nationwide, navigable, navigate, NAVIGATOR, NDA, neovascular, Nephew, neutrality, NIAID, nonbiologic, nonfederal, NYVEPRIA, occlusion, occupancy, OCS, OECD, Olpasiran, OneTen, onset, ORR, outbreak, output, outreach, overcome, overseen, pandemic, PASI, paused, pausing, physically, portal, postmarketing, precipitate, precipitated, prepaid, prepandemic, PRIDE, proliferation, proportion, proportionate, protocol, Purple, pushed, quartile, RBC, reassessment, recession, recommenced, redemption, reimpose, remote, remotely, renamed, representation, resource, respiratory, resurgence, resurgent, retaliatory, retinal, retinopathy, reverification, reward, rheumatology, RIABNITM, RINVOQ, RNA, root, RTOR, School, score, semiannual, Shank, Siebert, signification, siRNA, Smith, SoC, softened, sotorasib, speaker, sPGA, spread, Stafford, stakeholder, static, STELARA, Stivarga, strain, Subcontinent, surface, surge, tackle, talent, TBA, temperature, threat, timeline, Tokyo, training, trajectory, transmission, travel, turnover, UCLA, UDENYCA, unamortized, underemployment, underrepresentation, unemployment, uninsured, ustekinumab, vaccination, Van, vascular, VEGFR, vein, verified, virtual, Warehouse, Wegener, wet, wider, winter, workplace, writ, Xeljanz
Removed: AAA, advisory, Alzheimer, amyloid, atopic, augment, BACE, BLA, cardiac, construing, Cynthia, damage, decided, deCODE, deducting, Dermatology, Dezima, discontinuation, footprint, force, Galenica, Genentech, genome, grew, henderson, hold, Hope, hyperparathyroidism, impacting, Leonard, lessen, lesser, loan, margin, meline, Merck, Mimpara, MIRCERA, moot, moved, mutually, myosin, narrow, noncompliance, overhaul, pain, patentability, Patton, presidential, PROCRIT, properly, propose, reacquired, rebecca, reshaping, retained, revalue, SCAN, Schaeffer, sector, Servier, showing, sNDA, sorafenib, threshold, track, validation, vitamin


Methods to Determine the Presence of an Antibody that Binds Modified Human Thymic Stromal Lymphopoietin (TSLP)
8 Apr 21
Modified, furin resistant human TSLP polypeptides and polynucleotides encoding the modified human TSLP polypeptides are provided.
INTERLEUKIN-2 Muteins for the Expansion of T-regulatory Cells
1 Apr 21
Provided herein are IL-2 muteins and IL-2 mutein Fc-fusion molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production.
Method for Making Injectable Pharmaceutical Compositions
1 Apr 21
The invention relates to methods for making injectable pharmaceutical compositions wherein particles present in the compositions are detected and analyzed, and the acceptance of the compositions is determined based on chemical and physical properties as well as toxicology and patient risks associated of the particles.
Pacap Antibodies and Uses Thereof
1 Apr 21
The present invention relates to monoclonal antibodies that specifically bind to human pituitary adenylate cyclase activating polypeptide (PACAP) and pharmaceutical compositions comprising such antibodies.
1 Apr 21
Pharmaceutical compositions and single unit dosage forms of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetylaminoisoindoline-1,3-dione, or a pharmaceutically acceptable stereoisomer, prodrug, salt, solvate, hydrate, or clathrate thereof, are provided herein.